Inflammatory and metabolic markers mediate the association of hepatic steatosis and fibrosis with 10-year ASCVD risk.

Association between hepatic steatosis, liver fibrosis, Hs-CRP, HOMA-IR, and predicted 10-year ASCVD risk Table 2 shows that, compared to the first quartile (Q1), each increase in the quartile of CAP is associated with an increased odds ratio (OR) and 95% confidence interval (CI) for predicted moderate-to-high 10-year ASCVD risk: 1.14 (0.89, 1.45), 1.37 (1.08, 1.73), 2.44 (1.93, 3.10), with a significant trend ( p < 0.001).

also in 9,775 other papers

In the Q4 group, SII demonstrated a strong association with ASCVD risk (OR 1.28, 95% CI: 0.99, 1.65), although it did not reach statistical significance ( p = 0.064).

also in 111,027 other papers